Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Glomerular common gamma chain confers B- and T-cell-independent protection against glomerulonephritis.

Luque Y, Cathelin D, Vandermeersch S, Xu X, Sohier J, Placier S, Xu-Dubois YC, Louis K, Hertig A, Bories JC, Vasseur F, Campagne F, Di Santo JP, Vosshenrich C, Rondeau E, Mesnard L.

Kidney Int. 2017 May;91(5):1146-1158. doi: 10.1016/j.kint.2016.10.037. Epub 2017 Jan 19.

2.

Innate-like and conventional T cell populations from hemodialyzed and kidney transplanted patients are equally compromised.

Baron M, Belo R, Cathelin D, Moreira-Teixeira L, Cartery C, Rondeau E, Mesnard L, Leite-de-Moraes M.

PLoS One. 2014 Aug 21;9(8):e105422. doi: 10.1371/journal.pone.0105422. eCollection 2014.

3.

Genetic background-dependent thrombotic microangiopathy is related to vascular endothelial growth factor receptor 2 signaling during anti-glomerular basement membrane glomerulonephritis in mice.

Mesnard L, Cathelin D, Vandermeersch S, Rafat C, Luque Y, Sohier J, Nochy D, Garcon L, Callard P, Jouanneau C, Verpont MC, Tharaux PL, Hertig A, Rondeau E.

Am J Pathol. 2014 Sep;184(9):2438-49. doi: 10.1016/j.ajpath.2014.05.020. Epub 2014 Jul 6.

PMID:
25005449
4.

Targeting connexin 43 protects against the progression of experimental chronic kidney disease in mice.

Abed A, Toubas J, Kavvadas P, Authier F, Cathelin D, Alfieri C, Boffa JJ, Dussaule JC, Chatziantoniou C, Chadjichristos CE.

Kidney Int. 2014 Oct;86(4):768-79. doi: 10.1038/ki.2014.108. Epub 2014 May 21.

5.

Administration of recombinant soluble urokinase receptor per se is not sufficient to induce podocyte alterations and proteinuria in mice.

Cathelin D, Placier S, Ploug M, Verpont MC, Vandermeersch S, Luque Y, Hertig A, Rondeau E, Mesnard L.

J Am Soc Nephrol. 2014 Aug;25(8):1662-8. doi: 10.1681/ASN.2013040425. Epub 2014 May 1.

6.

Expression of TLR9 in tumor-infiltrating mononuclear cells enhances angiogenesis and is associated with a worse survival in lung cancer.

Belmont L, Rabbe N, Antoine M, Cathelin D, Guignabert C, Kurie J, Cadranel J, Wislez M.

Int J Cancer. 2014 Feb 15;134(4):765-77. doi: 10.1002/ijc.28413. Epub 2013 Sep 4.

7.

Silencing of the glucocorticoid-induced leucine zipper improves the immunogenicity of clinical-grade dendritic cells.

Cathelin D, Met Ö, Svane IM.

Cytotherapy. 2013 Jun;15(6):740-9. doi: 10.1016/j.jcyt.2013.02.005.

PMID:
23643305
8.

Vitronectin dictates intraglomerular fibrinolysis in immune-mediated glomerulonephritis.

Mesnard L, Rafat C, Vandermeersch S, Hertig A, Cathelin D, Xu-Dubois YC, Jouanneau C, Keller AC, Ribeil JA, Leite-de-Moraes MC, Rondeau E.

FASEB J. 2011 Oct;25(10):3543-53. doi: 10.1096/fj.11-180752. Epub 2011 Jul 15.

PMID:
21764994
9.

Dendritic cell-tumor cell hybrids and immunotherapy: what's next?

Cathelin D, Nicolas A, Bouchot A, Fraszczak J, Labbé J, Bonnotte B.

Cytotherapy. 2011 Aug;13(7):774-85. doi: 10.3109/14653249.2011.553593. Epub 2011 Feb 7.

PMID:
21299362
10.

Peroxynitrite-dependent killing of cancer cells and presentation of released tumor antigens by activated dendritic cells.

Fraszczak J, Trad M, Janikashvili N, Cathelin D, Lakomy D, Granci V, Morizot A, Audia S, Micheau O, Lagrost L, Katsanis E, Solary E, Larmonier N, Bonnotte B.

J Immunol. 2010 Feb 15;184(4):1876-84. doi: 10.4049/jimmunol.0900831. Epub 2010 Jan 20.

11.

Tumor cells can escape DNA-damaging cisplatin through DNA endoreduplication and reversible polyploidy.

Puig PE, Guilly MN, Bouchot A, Droin N, Cathelin D, Bouyer F, Favier L, Ghiringhelli F, Kroemer G, Solary E, Martin F, Chauffert B.

Cell Biol Int. 2008 Sep;32(9):1031-43. doi: 10.1016/j.cellbi.2008.04.021. Epub 2008 May 2.

PMID:
18550395
12.

Increase of CD4+ CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+ CD25+ T lymphocytes.

Audia S, Nicolas A, Cathelin D, Larmonier N, Ferrand C, Foucher P, Fanton A, Bergoin E, Maynadie M, Arnould L, Bateman A, Lorcerie B, Solary E, Chauffert B, Bonnotte B.

Clin Exp Immunol. 2007 Dec;150(3):523-30. Epub 2007 Oct 22.

13.

Dendritic cells trigger tumor cell death by a nitric oxide-dependent mechanism.

Nicolas A, Cathelin D, Larmonier N, Fraszczak J, Puig PE, Bouchot A, Bateman A, Solary E, Bonnotte B.

J Immunol. 2007 Jul 15;179(2):812-8.

14.

The inhibition of TNF-alpha anti-tumoral properties by blocking antibodies promotes tumor growth in a rat model.

Larmonier N, Cathelin D, Larmonier C, Nicolas A, Merino D, Janikashvili N, Audia S, Bateman A, Thompson J, Kottke T, Hartung T, Katsanis E, Vile R, Bonnotte B.

Exp Cell Res. 2007 Jul 1;313(11):2345-55. Epub 2007 Mar 30.

PMID:
17466973
15.

Apoptotic, necrotic, or fused tumor cells: an equivalent source of antigen for dendritic cell loading.

Larmonier N, Mérino D, Nicolas A, Cathelin D, Besson A, Bateman A, Solary E, Martin F, Katsanis E, Bonnotte B.

Apoptosis. 2006 Sep;11(9):1513-24.

PMID:
16738802
16.

CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative.

Ghiringhelli F, Larmonier N, Schmitt E, Parcellier A, Cathelin D, Garrido C, Chauffert B, Solary E, Bonnotte B, Martin F.

Eur J Immunol. 2004 Feb;34(2):336-44.

Supplemental Content

Loading ...
Support Center